Table 1.
Patient characteristics.
| Characteristics | n | Range/Percentage |
|---|---|---|
| Age (years) | 65.5 | 20–93 |
| Sex(male) | 23 | 44.2% |
| Staging IV | 39 | 75% |
| ECOG 0–1 | 48 | 92.3% |
| Normal liver function | 48 | 92.3% |
| Normal renal function | 48 | 92.3% |
| Biomarkers | ||
| MMR | 8 | 15.4% |
| EBER | 5 | 9.6% |
| PD-L1 | ||
| ≥1 | 29 | 55.8% |
| ≥5 | 9 | 17.3% |
| ≥10 | 6 | 11.5% |
| Lines of treatment | ||
| 1st | 10 | 19.2% |
| 2nd | 10 | 19.2% |
| 3rd or later | 32 | 61.5% |
| Immunotherapy | ||
| Nivolumab | 38 | 73.1% |
| Pembrolizumab | 12 | 23.1% |
| Atezolizumab | 2 | 3.8% |
| Treatment courses | 6 | 1–64 |
| Previous therapies | ||
| Previous surgery | ||
| Curative | 19 | 36.5% |
| Palliative | 12 | 23.1% |
| No surgery | 21 | 40.4% |
| RT at primary tumor | 12 | 23.1% |
| Cisplatin | 10 | 19.2% |
| Oxaliplatin | 32 | 61.5% |
| 5-FU | 22 | 42.3% |
| Taxanes | 27 | 51.9% |
Population: six patients with both MSI-H and CPS ≥ 1 and four patients with both EBER and CPS ≥ 1. No patient had both MSI-H and EBER.